peripheral T cell lymphoma
Conditions
Interventions
Case series:maintain treatment of chidamide
Sponsors
Department of Hematology, Xinqiao Hospital, Third Military Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Newly diagnosed peripheral T-cell lymphomas(PTCL), except ALK+ anaplastic large cell lymphoma(ALK+ALCL);The patients achieved = partial remission(PR) after 6 cycles of ECHOP, and then received autologous peripheral blood stem cell transplantation(APBSCT); Hematopoietic reconstitution is stable and the primary disease is stable,30-45d after APBSCT. And meet the following criteria: 1.Aged60, Estimated lifetime>3 months 2.No sever organ dysfunction (1) Cr55%; (4) Hb>9g/dL, Bilirubin<2.0mg/dl; 3. Voluntary participants, informed consent.
Exclusion criteria
Exclusion criteria: 1. Severe cardiac, renal or hepatic dysfunction; 2. Patients have other malignant cancer and must receive treatment; 3. Patients cant understand or follow study protocol due to clinical symptoms of brain dysfunction or serious mental illness; 4. Patients cant guarantee to accomplish treatment plan and follow-up; 5. Patients with severe acute hypersensitive reaction; 6. Uncontrolled active infection; 7. Patients who have been enrolled in other clinical trial; 8. Patients arent suitable for this clinical trial according to investigators judgement.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| recurrence rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| leukopenia;anemia;thrombocytopenia;gastrointestinal reaction;liver damage;renal damage; | — |
Countries
China
Contacts
Public ContactXi Zhang
Department of Hematology, Xinqiao Hospital, Third Military Medical University
Outcome results
None listed